Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

180 Life Sciences Corp (NQ: ATNF )

1.180 -0.020 (-1.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about 180 Life Sciences Corp

< Previous 1 2 Next >
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on $3M Registered Direct Offering, Concurrent Private Placement
Via Investor Brand Network
180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces $3M Registered Direct, Concurrent Private Placement
Via Investor Brand Network
180 Life Sciences Corp. (NASDAQ: ATNF) Near the Top of Equities by Percentage Gain on 4/5
Via Investor Brand Network
Topics Derivatives
Exposures Derivatives
180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement
Priced At-The-Market Under Nasdaq Rules 
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Summer Research Conference
Via Investor Brand Network
180 Life Sciences Announces Presentation at the Gordon Conference
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Update on Change of Status for Anti-TNF Frozen Shoulder Trial, Receives Patent Notification
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
From 180 Life Sciences Corp.
Via GlobeNewswire
180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Medical Advisory Board Chair Coauthors Review of Early Stage Dupuytren’s Disease Treatment
Via Investor Brand Network
180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Engages Kinexum for Assistance in MAA Submission
Via Investor Brand Network
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
From 180 Life Sciences Corp.
Via GlobeNewswire
Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)
From Newman Ferrara LLP
Via Business Wire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Is Notified by NASDAQ Exchange of Full Compliance
Via Investor Brand Network
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Review on Molecular Basis of Dupuytren’s Disease
Via Investor Brand Network
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Shareholder Letter with Corporate Update
Via Investor Brand Network
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Closes on Registered Direct Offering for $6M
Via Investor Brand Network
180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Enters into Registered Direct Offering Agreement for $6M Proceeds
Via Investor Brand Network
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From 180 Life Sciences Corp.
Via GlobeNewswire
180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Releases Status Update on MHRA Interaction
Via Investor Brand Network
180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture
From 180 Life Sciences Corp.
Via GlobeNewswire
InvestorNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Announces Participation in Upcoming Biotech Conference
Via Investor Brand Network
180 Life Sciences to Participate in A.G.P.’s Virtual Biotech Conference to be Held November 30 – December 1, 2022
From 180 Life Sciences Corp.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.